COCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
COCO looks like a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong fundamental momentum, positive analyst revisions, and favorable option sentiment. While the technical picture is not perfectly aligned for a chase entry, the overall setup still supports buying now rather than waiting.
The stock is trading near 78.05, just below the recent close of 78.65 and close to pivot resistance at 76.03 with nearby resistance at 79.17. MACD histogram is negative at -0.625, but it is contracting, which suggests downside momentum is weakening. RSI at 71.37 is elevated but still labeled neutral in the provided data, and moving averages are converging, indicating a consolidating trend rather than a strong breakdown. Overall, the chart shows a bullish medium-term structure with near-term resistance around 79.17 and 81.11.
Recent news is clearly positive: Vita Coco posted Q1 2026 net sales of $180 million, up 37% year over year, and raised full-year sales guidance. The company also holds about 51% to 52% of the U.S. coconut water market, giving it a strong category leadership position and a favorable long-term growth narrative. Analyst commentary repeatedly highlights durable sales momentum, strong volume growth, and improved margins. BofA raised its target to $85 and kept a Buy rating, reinforcing upside potential.
The main negative factor is that the technicals do not show a clean breakout signal today: MACD is still below zero, and the stock is sitting near resistance after a strong run. There is also no AI Stock Picker or SwingMax trigger today, so there is no proprietary signal-driven urgency. Hedge funds and insiders are neutral, and there is no congress trading data to add conviction from political activity.
Latest quarter: Q1 2026. Vita Coco delivered net sales of $180 million, up 37% year over year, which is a very strong growth rate for a consumer staples-related company. The news also indicates raised full-year sales guidance and stronger volume momentum, suggesting the quarter was not just a one-off revenue beat but part of a continuing growth trend. The latest quarter clearly shows accelerating top-line growth and improving business execution.
Analyst sentiment is positive and improving. Multiple firms raised price targets after Q1, including BofA to $85 from $72, Jefferies to $78 from $63, Evercore to $75 from $70, Goldman Sachs to $71 from $62, and Piper Sandler to $70 from $59. The only mixed note is Morgan Stanley, which kept an Equal Weight rating due to valuation and balanced risk/reward after strong outperformance. Wall Street’s pros view is that sales momentum, market share gains, and margin expansion are durable; the con view is that the stock has already rerated significantly, leaving less upside than earlier in the year.
